Search company, investor...

Peptimmune

peptimmune.com

Founded Year

2002

Stage

Dead | Dead

Total Raised

$83.55M

About Peptimmune

Peptimmune develops drugs for the treatment of various autoimmune diseases.

Headquarters Location

64 Sidney Street Suite 380

Cambridge, Massachusetts, 02139,

United States

617-715-8000

Missing: Peptimmune's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Peptimmune's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Peptimmune Patents

Peptimmune has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/17/2005

2/2/2010

Autoimmune diseases, Immune system, Immunology, Clusters of differentiation, Transcription factors

Grant

Application Date

11/17/2005

Grant Date

2/2/2010

Title

Related Topics

Autoimmune diseases, Immune system, Immunology, Clusters of differentiation, Transcription factors

Status

Grant

Latest Peptimmune News

Peptimmune Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 5, 2016

Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 14:35 EST 5 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Peptimmune, Inc. since January 2007. Key Findings Provides intelligence on Peptimmune, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Peptimmune, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Peptimmune, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Peptimmune, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Peptimmune Frequently Asked Questions (FAQ)

  • When was Peptimmune founded?

    Peptimmune was founded in 2002.

  • Where is Peptimmune's headquarters?

    Peptimmune's headquarters is located at 64 Sidney Street, Cambridge.

  • What is Peptimmune's latest funding round?

    Peptimmune's latest funding round is Dead.

  • How much did Peptimmune raise?

    Peptimmune raised a total of $83.55M.

  • Who are the investors of Peptimmune?

    Investors of Peptimmune include MPM Capital, New Enterprise Associates, Boston Medical Investors, Covera Ventures, Silicon Valley Bank and 7 more.

  • Who are Peptimmune's competitors?

    Competitors of Peptimmune include Tobira Therapeutics, Selecta Biosciences, MacroGenics, Micromet, Virdante Pharmaceuticals and 13 more.

Compare Peptimmune to Competitors

L
LaGray

LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.

V
Velbionanotechnology

Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn

P
Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

B
BioMs

BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.

N
NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

A
AiRNA Pharmaceuticals

AiRNA's focus is to develop RNAi drugs for cancer, inflammation, and infectious diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.